IADVL SIG Recalcitrant Dermatophytosis Position Statement on Super Bioavailable Itraconazole

Nayankumar H Patel; Kabir Sardana; Manjunath M Shenoy; Madhu Rengasamy; Ananta Khurana; Sunil Ghate; Chalam Konakanchi Venkata; Yogesh Marfatiya; Deblina Bhunia; Jyothi Jayaraman; Anupam Das; Akshay Kumar Jain

doi:10.4103/idoj.idoj_668_22

IADVL SIG Recalcitrant Dermatophytosis Position Statement on Super Bioavailable Itraconazole

Indian Dermatol Online J. 2023 Dec 1;15(1):1-7. doi: 10.4103/idoj.idoj_668_22. eCollection 2024 Jan-Feb.

Authors

Affiliations

¹ Department of DVL, GCS Medical College Hospital and Research Centre, Ahmedabad, Gujarat, India.
² Department of Dermatology, Dr. Ram Manohar Lohia Hospital and Atal Bihari Vajpayee Institute of Medical Sciences, New Delhi, India.
³ Department of DVL, Yenepoya Medical College, Mangalore, Karnataka, India.
⁴ Department of DVL, Madras Medical College, Chennai, Tamil Nadu, India.
⁵ Dr. Ghate's Skin, Hair and LASER Centre, Mumbai, Maharashtra, India.
⁶ Government Medical College, Srikakulam, Andhra Pradesh, India.
⁷ SBKS MI and RC, Piparia, Waghodia, Vadodara, Gujarat, India.
⁸ M.G.M. Medical College, Kishanganj, Bihar, India.
⁹ Department of Dermatology, Father Muller Medical College, Manglore, Karnataka, India.
¹⁰ Department of DVL, KPC Medical College and Hospital, Kolkata, West Bengal, India.
¹¹ GMC, Kota, Rajasthan, India.

Abstract

Itraconazole (ITZ) has been the mainstay of oral antifungal treatment for the current epidemic of recalcitrant dermatophytosis (RD) in India. Recently, a newer formulation of ITZ, super bioavailable itraconazole (SUBA-ITZ), is made available in the market by many pharmaceutical companies. It is important for dermatologists to understand the pharmacokinetic properties of SUBA-ITZ vis-a-vis conventional pellet formulation to use it effectively and safely. Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) has established a special interest group for recalcitrant dermatophytosis (SIG-RD) to strengthen research, continuing medical education, and industry collaboration on the subject. This position statement on SUBA-ITZ by SIG-RD is an attempt to address current pieces of evidence and the position of this new formulation in the management of RD.

Keywords: Dermatophytosis; SUBA itraconazole; position paper.